Characterization of two receptors for TRAIL
		1The accession numbers (BankIt) for the two TRAIL receptor cDNA sequences reported in this paper are 130586 (TRAIL-R2) and 130595 (TRAIL-R3).1  by Schneider, Pascal et al.
FEBS 19379 FEBS Letters 416 (1997) 329-334 
Characterization of two receptors for TRAIL 
Pascal Schneider1, Jean-Luc Bodmerla, Margot Thomea, Kay Hofmann*3, Nils Hollera, 
Jürg Tschoppa* 
^Institute of Biochemistry, University of Lausanne, Chemin des Boveresses 155, CH-1066 Epalinges, Switzerland 
bSwiss Institute for Experimental Cancer Research, BIL Research Center, Chemin des Boveresses 155, CH-1066 Epalinges, Switzerland 
Received 24 September 1997 
Abstract Two receptors for TRAIL, designated TRAIL-R2 
and TRAIL-R3, have been identified. Both are members of the 
tumor necrosis factor receptor family. TRAIL-R2 is structurally 
similar to the death-domain-containing receptor TRAIL-R1 
(DR-4), and is capable of inducing apoptosis. In contrast, 
TRAIL-R3 does not promote cell death. TRAIL-R3 is highly 
glycosylated and is membrane bound via a putative phosphatid-
ylinositol anchor. The extended structure of TRAIL-R3 is due to 
the presence of multiple threonine-, alanine-, proline- and 
glutamine-rich repeats (TAPE repeats). TRAIL-R2 shows a 
broad tissue distribution, whereas the expression of TRAIL-R3 is 
restricted to peripheral blood lymphocytes (PBLs) and skeletal 
muscle. All three TRAIL receptors bind TRAIL with similar 
affinity, suggesting a complex regulation of TRAIL-mediated 
signals. 
© 1997 Federation of European Biochemical Societies. 
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1. Introduction 
Members of the tumor necrosis factor (TNF) receptor fam-
ily are type I membrane molecules containing multiple cys-
teine-rich repeats in their extracellular domain. The cytoplas-
mic portions generally lack sequence homology with the 
exception of a motif called the 'death domain ' (DD) which 
is found in four of the family members: Fas [1,2], T N F - R 1 
[3], T R A M P (wsl/Apo-3/DR-3) [4-7] and T R A I L - R (DR-4) 
[8]. These four receptors efficiently transmit death signals 
through DD-containing adaptor proteins. T R A I L receptor 
(TRAIL-R) is the most recently identified death receptor [8]. 
Its ligand T R A I L shows a broad tissue distribution [9] and, 
like FasL, induces rapid apoptosis of various transformed 
TRAIL-R-posit ive cell lines [9-11]. We and others have re-
cently characterized a family of viral and mammalian pro-
teins, called FLIPs , which interfere with death receptor signal-
ing pathways by binding to F A D D and F L I C E [12-18]. 
FLIPs block TRAIL-R-mediated death signals even though 
it has been reported that T R A I L - R transmit signals independ-
ently of F A D D [8,11]. We therefore considered the possibility 
that an as yet unknown alternative T R A I L receptor exists 
that signals through the F A D D - F L I C E pathway. Here we 
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report on the identification and the structural and functional 
characterization of two novel receptors for TRAIL. 
2. Materials and methods 
2.1. Reagents and cell lines 
A Flag-tagged version of the extracellular domain (residues 139-
281) of human Fas:Fc and human TNFRl:Fc was produced in 293 
HEK cells [19]. Flag-tagged recombinant soluble human TRAIL (res-
idues Thr95-Gly281) [13] and Flag-tagged human TNFoc (residues 
Ser85-Leu233) were produced in bacteria. 
2.2. Northern blot analysis 
Northern blot analysis was performed using Human Multiple Tis-
sue Northern Blots I and II (Clontech #7760-1 and #7759-1). The 
membranes were incubated in ExpressHyb hybridization solution 
(Clontech #8015-1) for at least 1 h at 62°C. The random-primed 
cDNA probes (Boehringer Mannheim) were synthesized using the 
extracellular domains of TRAIL-R 1 and TRAIL-R3 and the intra-
cellular domain of TRAIL-R2 as template. The heat-denatured cDNA 
probe was added at 1.5 x 106 cpm/ml in fresh ExpressHyb. The mem-
brane was hybridized for 12-24 h at 62°C, washed three times in 
2XSSC containing 0.05% SDS and exposed at -70°C. 
2.3. Cloning of TRAIL receptor cDNA 
Several EST clones that potentially encoded novel TRAIL receptors 
were identified in the dbEST data base at the National Center for 
Biotechnology Information by performing a data base search using 
the generalized profile method [20] based on the sequence homology 
to the N-terminal domain of TRAIL-R1. Two clones from a cDNA 
library of the Ntera-2 neuroepithelial cell line encoded TRAIL-R2 
(GenBank accession numbers: AA223440 and AA223122). Two 
clones from a cDNA library of human pregnant uterus (GenBank 
accession numbers: AA031883 and AA150849) and one clone from 
a cDNA library of human fetal liver and spleen (GenBank accession 
number: T71406) encoded TRAIL-R3. The inserts were sequenced by 
conventional methods, and the resulting sequences were aligned. 
The 4 kbp long insert of clone AA223440 had a 106 bp deletion 
(bases 146-251, the A of the ATG being base number 1) when com-
pared to clone AA223122. This deletion resulted in both a frame shift 
and a loss of homology with TRAIL-R 1 and was obviously not the 
result of alternative splicing. As we were unable to obtain the expected 
sequence from clone AA223122 supplied by two different companies, 
we generated a complete cDNA coding for TRAIL-R2 using a double 
PCR approach with primers designed on the sequence of clone 
AA223122. In a first round of the PCR, two products were produced 
with clone AA223440 as template using (a) the forward oligonucleo-
tide 5'-AAGCTTGCCACCATGGAACAACGGGGACAGAACGC-
CCCG-3' and primer 5'-GGCCCCACAACAAAAGAGGTCCAG-
CCCCTCAGAGGGATTGTGTCCACCTGGACACCATATCTC-3' 
, and (b) the reverse oligonucleotide 5'-TTAGGACATGGCAGAGT-
CTGCATTACC-3' and primer 5'-CTTTTGTTGTGGGGCCACTC-
TCTGCTGGGGAGCTAGGTCTTGTTGGGTGATCAGAGCAG-
ACTCAGCTGAGACCAACAGCAGGACCG-3'. These purified 
PCR products, containing the 5' and 3' portions of TRAIL-R2, re-
spectively, were then mixed and allowed to undergo three cycles of 
PCR before amplification with the forward and reverse oligonucleo-
tides described above. 
2.4. TRAIL receptor expression vectors 
Full length TRAIL-R 1 (aa 1^+65), TRAIL-R2 (aa 1^139) and 
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TRAIL-R3 (aa 1-259) and their respective extracellular domains 
(TRAIL-Rl, aa 1-239; TRAIL-R2, aa 1-211; and TRAIL-R3, aa 
1-240) were amplified by PCR with primers containing suitable re-
striction sites and 5' Kozak consensus sequence [21]. An EST clone 
(GenBank accession number: AA 100865) was used as a template for 
TRAIL-Rl amplification. PCR products were cloned into pCRO-blunt 
(InVitroGen), then subcloned into the pCRIII mammalian expression 
vector (InVitroGen) as HindlWXhol fragments for full length recep-
tors or, for extracellular domains, as HindHllSaK fragments in frame 
with a SaWNotl cDNA cassette encoding the hinge, CH2 and CH3 
domains (aa residues 231^47) of human IgGl [22]. TRAIL-R3 (aa 
25-240) was amplified by PCR and cloned into the PstI and EcoRl 
sites of the pCRIII-derived vector pHAFlag [19], in frame with the 
signal peptide of hemagglutinin and a Flag epitope. The resulting 
plasmid, pHAFlag-TRAIL-R3, was digested with Sma\ and religated 
to yield pHAFlag-TRAIL-R3A4 which lacks four out of the five 
threonine-, alanine-, proline- and glutamine-rich (TAPE) repeats. 
2.5. Identification of N- and O-linked glycosylation using DIG-labeled 
lectins 
Lectin binding to TRAIL-R3 was performed using the DIG Glycan 
Differentiation Kit (Boehringer Mannheim) according to the manu-
facturer's instructions. Briefly, purified TRAIL-R3 (about 1 μg pro-
tein for peanut agglutinin and 0.1 μg for other lectins) was subjected 
to SDS-PAGE and Western blotting, together with 1 μg of the proper 
control glycoprotein. After blocking, the lectins were allowed to bind 
for 1 h at room temperature in 10 mM Tris-HCl pH 7.5, 140 mM 
NaCl, 1 mM CaCl2, 1 mM MgCl2 and 1 mM MnCl2. After incuba-
tion with anti-DIG alkaline phosphatase conjugate, bound lectins 
were revealed using 5-bromo-4-chloro-3-indolyl phosphate and nitro-
blue tetrazolium chloride. 
2.6. Enzymatic treatments of TRAIL-R3 
Peptide 7V-glycanase F: Flag-TRAIL-R3 was heated in 20 μΐ of 
0.5% SDS, 1% 2-mercaptoethanol for 3 min at 95°C. Samples were 
cooled and supplemented with 10% Nonidet P-40 (2 μΐ) and 0.5 M 
sodium phosphate pH 7.5 (2 μΐ). Peptide N-glycanase F (125 U/μΙ, 
1 μΐ) was added (or omitted in controls), and samples were incubated 
for 3 h at 37°C prior to analysis by Western blotting. 
2.7. In vitro translation 
Plasmids containing the cDNAs coding for TRAIL receptors were 
Fig. 1. Predicted amino acid sequence of TRAIL-R2 and TRAIL-R3 and their homology with TRAIL-Rl (DR-4). A: Amino acid sequence 
alignment of human TRAIL-Rl (DR-4), TRAIL-R2, and TRAIL-R3. Sequence numbering starts at the predicted signal peptide, the predicted 
start of the respective mature proteins is indicated by arrowheads (1 and Г for TRAIL-Rl, 2/3 for TRAIL-R2 and -R3). The cysteine-rich do-
mains (Cys I-II), the transmembrane segment (TM) and the death domain (DD) are indicated. The membrane proximal extracellular part of 
TRAIL-R2 and -R3 contains a highly conserved stretch of 15 aa (TAPE repeat) which is present once in TRAIL-R2 (TAPE 1) and five times 
in TRAIL-R3 (TAPE 1-5). The potential attachment site for a glycolipid anchor on TRAIL-R3 (Ala236) is indicated with an arrow, and the 
putative carboxy-terminal signal sequence of the glycosyl phosphatidylinositol (GPI) addition is underlined. Potential TV-glycosylation sites (one 
in TRAIL-Rl, none in TRAIL-R2 and five in TRAIL-R3) and O-glycosylation sites present in the TAPE region of TRAIL-R3 are indicated 
by dots and asterisks, respectively. Identical and similar residues are represented in black and shaded boxes, respectively. B: Schematic repre-
sentation of the TRAIL receptors and the Flag-tagged expression constructs of TRAIL-R3 (Flag-TRAIL-R3) and TRAIL-R3 lacking four 
TAPE repeats (Flag-TRAIL-R3A4). SP, predicted signal peptides; HA, hemagglutinin signal peptide. 
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Fig. 2. TRAIL-R2 and TRAIL-R3 selectively bind TRAIL. A: Wells of microtiter ELISA plates were coated with fusion proteins of the indi-
cated TNF receptor family members with human IgG Fc (rec:Fc), and binding of the Flag-tagged ligands detected with anti-Flag antibodies. 
In the control panel, no receptor was adsorbed onto the plate. B: As in A, but binding of the TNF ligand family members to the respective re-
ceptor :Fc constructs was tested at the ligand concentrations indicated in the figure. 
in vitro translated using a coupled rabbit reticulocyte lysate system 
(TNT, Promega, USA) according to the manufacturer's instructions. 
Reaction volumes were 10 μΐ and contained 0.4 μg cDNA, 0.2 μΐ Τ7 
TNT polymerase, 4 U RNAsin (Boehringer) and 5 μ€ι 
[35S]methionine/cysteine. The reaction mixture was incubated at 
30°C for 90 min and 10% of the reaction was subjected to SDS-
PAGE under reducing conditions. 
2.8. Ligand binding assay 
Ligand binding assays were performed as previously described [19]. 
In brief, 96 well ELISA plates were coated with the receptor-Fc con-
structs (1 μg/ml in PBS, 100 μΐ, 2-16 h, 37°C). After saturation in 
blocking buffer (PBS containing 5% fetal calf serum, 1 h, 37°C) and 
three washes, Flag-tagged ligands were added (1 μg/ml in PBS con-
taining 0.5% fetal calf serum, 100 μΐ, 1 h, 37°C, when not stated 
otherwise). Bound ligands were revealed with anti-Flag antibody (1 
μg/ml in blocking buffer, 100 μΐ, 30 min, 37°C), rabbit anti-mouse IgG 
coupled to peroxidase (1/1000 dilution in blocking buffer, 100 μΐ, 30 
min, 37°C) and o-phenylenediamine hydrochloride (0.3 mg/ml in 50 
mM citric acid, 100 mM Na2HP04, 0.01% H202). Absorbance was 
taken at 490 nm with an ELISA reader. 
which is repeated five times within the protein (TAPE re-
peats). The five TAPE repeats present in TRAIL-R3 are re-
markably conserved diverging in only one out of the 15 aa 
positions. A single TAPE repeat is also present in TRAIL-R2, 
but not in TRAIL-R1, at a similar location (Fig. 1). More-
over, the cDNA sequence of TRAIL-R3 predicts a carboxy-
terminal stretch of 15 hydrophobic amino acid residues which 
is reminiscent of a signal for the addition of a glycosyl-phos-
phatidylinositol (GPI) anchor [23]. In a GPI-linked protein, 
the COOH-terminal portion of the nascent protein is cleaved 
off and exchanged for a preformed GPI anchor by the action 
of a GPI transamidase. A functional signal for GPI addition 
fulfils several sequence requirements [23]: first, the GPI ac-
3. Results 
3.1. Identification, expression and chromosomal localization of 
TRAIL-R2 and TRAIL-R3 
When the dbEST data base was searched using an im-
proved profile search [20] based on an optimal sequence align-
ment of TRAIL-R1 with all TNF receptor family members, 
two sets of candidate cDNA clones were found showing high 
sequence homology with the published sequence of the 
TRAIL-R (DR-4, which we call TRAIL-R1 for the sake of 
clarity) [8]. One set of cDNA clones predicted a membrane 
receptor encoding a polypeptide of 440 aa with an overall 
structural organization similar to TRAIL-R 1 (51% amino 
acid sequence identity). This receptor was named TRAIL-
R2 (see below). TRAIL-R2 contains two cysteine-rich repeat 
units in its extracellular region, followed by a predicted hydro-
phobic transmembrane segment and a 209 aa long cytoplas-
mic tail containing a typical 'death domain' (Fig. 1). The 
second set of cDNA clones predicted a protein containing 
259 aa. This short receptor (named TRAIL-R3) shows high 
sequence homology to both TRAIL-R 1 and TRAIL-R2 in the 
extracellular domain (60% and 52%> amino acid sequence iden-
tity, respectively), but ends immediately after a short predicted 
transmembrane domain (Fig. 1). Moreover, TRAIL-R3 con-
tains a characteristic motif of 15 aa, rich in Thr, Ala, Pro and 
Glu residues, before the predicted transmembrane domain, 
Fig. 3. Tissue distribution of TRAIL receptors. Northern blot anal-
ysis of poly(A+) RNA (2 μg per lane) of various human tissues us-
ing probes for TRAIL-R 1 (DR-4) (A), TRAIL-R2 (B) and TRAIL-
R3 (C). The blots were subsequently reprobed with ß-actin cDNA. 
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Fig. 4. Overexpression of TRAIL-Rl and TRAIL-R2, but not of TRAIL-R3 in 293T cells results in apoptosis. A: Morphology of 293T cells 
transiently overexpressing TRAIL-Rl, -R2 or -R3. Cells were transfected with the indicated full length receptors and analyzed 32 h later by 
phase contrast microscopy. The control shows 293T cells transfected with the empty vector. The bar corresponds to 50 μpiι. 
ceptor amino acid residue (at the ω site) and the amino acid 
residue at position ω+2 are small; second, the amino acid 
residue at position ω+l is different from Trp or Pro; and 
third, the presence of a hinge region located between position 
ω+З and approximately ω+8, followed by a stretch of approx-
imately 8-20 highly hydrophobic amino acids, is observed. 
According to this rule, Ala236 would be the predicted attach-
ment site for a GPI anchor in TRAIL-R3 (Fig. 1). 
The high sequence homology of the two novel receptors to 
TRAIL-Rl suggested that they probably interact with 
TRAIL. TRAIL-receptor:immunoglobulin Fc fusion proteins 
were constructed and their binding to soluble TRAIL 
(sTRAIL) was compared using an ELISA-based assay [7]. 
Each of the receptors interacted with TRAIL, whereas no 
binding was observed with TNFcc and sFasL (Fig. 2A). Signal 
intensities were comparable suggesting that the three TRAIL 
receptors bind TRAIL with similar affinities (Fig. 2B). 
3.2. Expression and chromosomal localization of TRAIL-R2 
and TRAIL-R3 
The expression pattern of TRAIL-R2 and -R3 in various 
tissues was examined by Northern blot analysis (Fig. 3). 
TRAIL-Rl [8] and TRAIL-R2 possessed a similar expression 
pattern and their respective mRNAs were detected in many 
tissues. While the TRAIL-Rl probe detected multiple tran-
scripts (2.6 kbp, 4.6 kbp, and 7.2 kbp) [8], only one 
TRAIL-R2 transcript (4.4 kbp) was detected by Northern 
blotting (Fig. 3B). In contrast to TRAIL-Rl and -R2, the 
expression of TRAIL-R3 (mRNA size, 1.2 kbp) was restricted 
to skeletal muscle, peripheral blood lymphocytes, and the 
spleen. 
For the determination of the chromosomal localization of 
the TRAIL-R, we took advantage of the known linkage of the 
EST clones to two sequence tagged sites (STS) [24]. The STS 
for TRAIL-Rl (STS: SHGC-9963) and TRAIL-R2 (STS: 
Fig. 5. TRAIL-R3: Glycosylation and the TAPE repeats. A: Western blot analysis under non-reducing conditions of the extracellular domains 
of Fas and TRAIL-Rl, -R2 and -R3 in fusion with IgG Fc (Fas:Fc, Rl:Fc, R2:Fc, R3:Fc). Protein A conjugated to peroxidase was used to 
reveal the blot. B: Western blot analysis of Flag-TRAIL-R3 expressed in 293T cells. The anti-Flag blot on the left hand side reveals a MT of 
65 kDa for the mature protein which decreases to 57 kDa upon the removal of TV-linked carbohydrates by peptide iV-glycanase F (PNGase F). 
Western blot showing Flag-TRAIL-R3 revealed with the lectins Galanthus nivalis agglutinin (GNA, detecting terminal a-Man residues), Maack-
ia amurensis agglutinin (MAA, detecting sialylated oligosaccharides) and peanut agglutinin (PNA, detecting O-linked core disaccharide) are 
shown in the other panels. C: SDS-PAGE analysis under reducing conditions of in vitro translation products of the TRAIL receptors (RI, R2, 
R3), of the Flag-tagged TRAIL-R3 with (Flag R3) or without the last four TAPE repeats (Flag-R3A4), and of the extracellular domain of 
the receptors fused to IgG Fc (Rl:Fc, R2:Fc, R3:Fc). The theoretically predicted loss of Μτ between Flag-R3 and Flag-R3A4 is 5.8 kDa. 
D: Western blot analysis of cellular Flag-TRAIL-R3 (R3) and Flag-TRAIL-R3A4 (R3A4) produced in 293T cells. Samples were prepared in 
SDS-PAGE sample buffer containig reducing agent (DTT). The blot was probed with anti-Flag antibodies. 
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WI-11701) both mapped to human chromosome 8, 44 cM 
from the top of the linkage map 8p 12-21, suggesting that 
the receptors are descendants of a common ancestral gene. 
3.3. TRAIL-R1 and TRAIL-R2 signal apoptosis 
The presence of a death domain in the cytoplasmic region 
of TRAIL-R2 suggested that activation of this receptor could 
result in the activation of a death signaling pathway. Experi-
ments with other death receptors have revealed that cell death 
can be induced in the absence of the respective ligand through 
the overexpression of the receptors only [7]. 293T cells trans-
fected with TRAIL-R1 or TRAIL-R2, examined 32 h after 
transfection, had rounded up and had undergone morpholog-
ical changes typical of apoptosis (Fig. 4). In contrast, over-
expression of TRAIL-R3 did not induce cytotoxic effects. 
3.4. Structure of TRAIL-R3 
While measuring the TRAIL-receptonFc-TRAIL interac-
tion (see Fig. 2), we found that the TRAIL-R3 fusion protein 
had an unexpectedly high apparent molecular mass when 
overexpressed in 293T cells (Fig. 5A). A theoretical Mx value 
of approximately 100 kDa was expected. However, only 
TRAIL-R1 and -R2 showed this expected value, whereas 
the Mr of the TRAIL-R3:Fc was > 180 kDa (Fig. 5A). Like-
wise, the expressed full length TRAIL-R3 exhibited an appar-
ent MT of 65 kDa under denaturing and reducing conditions 
instead of the theoretical MT value of 24.5 kDa (Fig. 5C), 
suggesting the presence of extensive posttranslational modifi-
cations and/or unusual structural motifs. 
This observation prompted us to analyze the carbohydrate 
modifications in TRAIL-R3. Upon incubation with peptide 
7V-glycanase F, the Μτ decreased by approximately 8 kDa 
(Fig. 5B), indicating that most of the five potential iV-glyco-
sylation sites (see Fig. 1) were glycosylated. These TV-linked 
oligosaccharides are most likely of the high-mannose type 
since TRAIL-R3 reacted with Galanthus nivalis agglutinin 
which recognizes terminal mannose residues in a(l-3), 
a(l-6) or oc(l-2) glycosidic linkages, and not with Sambucus 
nigra or Maackia amurensis agglutinins that recognize sialic 
acids in a(2-6) and a(2-3) glycosidic linkage to galactose 
(Fig. 5B, and data not shown). TRAIL-R3 also reacted with 
peanut agglutinin, a lectin that specifically binds to the unsia-
lylated Galßl-3GalNAc disaccharide core of O-linked carbo-
hydrates (Fig. 5B), indicating the presence of O-linked carbo-
hydrates. This is in concordance with the sequence of TRAIL-
R3 which reveals more than 20 potential O-linked glycosyla-
tion sites [25] in the TAPE repeat region only (see Fig. 1). 
However, the contribution of these posttranslational mod-
ifications on the Mx of TRAIL-R3 only partially explained its 
high apparent Μτ. When the complete TRAIL receptors, or 
their extracellular domains of the TRAIL receptors fused to 
IgG Fc, were in vitro translated in the absence of microsomal 
membranes, the expected MT for TRAIL-R3 was still consid-
erably higher than the predicted value (Fig. 5C). In contrast, 
the apparent molecular mass of TRAIL-R1 and TRAIL-R2 
roughly corresponded to the theoretical values. We therefore 
analyzed the effect of the TAPE repeats on the MI of TRAIL-
R3. A deletion mutant of Flag-TRAIL-R3 lacking four out of 
five TAPE repeats (Flag-TRAIL-R3A4) was constructed and 
Fig. 5C shows that this TAPE repeat-deficient receptor had an 
almost normal electrophoretic behavior by SDS-PAGE anal-
ysis. The large contribution of the TAPE repeats upon the MT 
of TRAIL-R3 was also evident when comparing the Μτ of 
TRAIL-R3 and TRAIL-R3A4 expressed in 293T cells (Fig. 
5D). 
4. Discussion 
We have characterized two novel receptors for TRAIL 
which we have named TRAIL-R2 and TRAIL-R3, bringing 
the current total number of TRAIL receptors to three, and of 
death receptors to five. TRAIL-R2 exhibits high structural 
and functional homology to TRAIL-R1 (DR-4). 
The genes for both TRAIL-R2 and TRAIL-R3 are clus-
tered on the same 8pl2-21 region of chromosome 8. No other 
genes of the TNF receptor family have been mapped to this 
region of chromosome 8. TRAMP, CD30-R, TNF-R2, and 
OX40-R have been mapped to chromosome 1. A second gene 
cluster has been found on chromosome 12 (CD27R, 12pl3; 
LTß-R, 12pl3; TNFR1, 12pl3.2) and the genes encoding Fas, 
CD40R, and NGFR are distributed on various other chromo-
somes. 
The sequences of TRAIL-R2 and TRAIL-R3 contain one 
and five repeat units of 15 amino acids (TAPE repeats) re-
spectively, which are located in the extracellular domain, close 
to the membrane interaction site. Both receptors are potent 
inducers of cell death. While this manuscript was in prepara-
tion, two other groups reported on the characterization of two 
TRAIL receptors, designated DR-5 and DcRl (TRID) 
[26,27]. Whereas the sequence of DcRl is identical to 
TRAIL-R3, DR-5 differs from TRAIL-R2 in that it lacks 
the TAPE repeat, suggesting that alternative splicing may oc-
cur. These TAPE repeat units are responsible for the anom-
alous migration of the receptors on SDS-PAGE gels (the 
TAPE repeats migrate approximately 4 times slower than pre-
dicted), a phenomenon which has already been observed in 
other polypeptides containing repetitive domains. For exam-
ple, several protozoan parasite proteins such as the circum-
sporozoite protein of Plasmodium falciparum [28] or the pro-
cyclin of Trypanosoma brucei [29] migrate on SDS-PAGE gels 
with apparent molecular weights significantly greater than the 
molecular weights predicted from their sequence. The same is 
true for some mammalian proteins such as the C-kinase sub-
strate (MARCKS) [30]. The Pro, Ala or Glu repeats of 
MARCKS are responsible for the rod-like structure of the 
protein (4.4 X 36 nm) [30], whereas a molecular model of the 
(Asp-Pro)2(Glu-Pro)29 sequence of procyclin indicates a struc-
ture of 18 nm in length for a diameter of 0.9 nm [31]. There-
fore, it is likely that the repeat units of TRAIL-R3 also adopt 
an elongated, rigid structure. TRAIL-R3 is then predicted to 
expose its ligand binding site out of the plane containing the 
binding sites of TRAIL-R1 and R2. 
The sequence of TRAIL-R3 also predicts several sites for 
posttranslational modifications including signal peptide cleav-
age, JV- and O-glycosylation and GPI addition. The predicted 
signal peptide cleavage sites of TRAIL-R2 and TRAIL-R3 
are found at corresponding positions, preceding the extracel-
lular two cysteine-rich domains by approximately 25 aa. In 
TRAIL-R1 the proposed putative signal peptide cleavage site 
is more distal (additional 86 aa separate the start of the ma-
ture protein from the cysteine-rich repeats, see Fig. 1), 
although a second cleavage site is predicted in the TRAIL-
Rl sequence at a position corresponding to the predicted site 
in TRAIL-R2 and TRAIL-R3. An antibody specifically react-
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ing with a peptide spanning amino acid residues 1-24 follow-
ing the first predicted signal peptidase cleavage site does not 
detect the T R A I L - R l : F c fusion protein (data not shown), 
suggesting that the second cleavage site is used in vivo. 
Both death-inducing T R A I L receptors show a broad tissue 
distribution. In contrast to mice treated with Fas ligand, mice 
survive the same dose of T R A I L (our unpublished observa-
tion) despite the high expression levels of T R A I L - R 1 and -R2 
in the liver. Targeted disruption of the T R A I L - R genes may 
therefore provide interesting insights into the physiological 
role of TRAIL-R. 
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